Australia's Emyria climbs to nearly two-month high on positive drug trial results

Emyria

04/02/2025 02:47

** Shares of Emyria  EMD.AX  rise 2.9% to A$0.036, their
highest levels since Dec 11
    ** The early-stage drug developer announces positive interim
analysis results of its MDMA-assisted therapy programme for Post
Traumatic Stress Disorder (PTSD)
    ** Co says therapy programme clinically reduces PTSD
symptoms in first eight patients
    ** Stock rose as much as 14.3% to A$0.040 earlier in the
day, marking its biggest intraday gain since Jan 22
    ** About 1.3 mln shares change hands, 6.9 times the 30-day
average of 189,038
    ** Stock has risen 5.9% YTD, including current session's
moves

    
    

 (Reporting by Manasi Dasa Sundeep in Bengaluru)
 ((Manasi.DasaSundeep@thomsonreuters.com;))